Capital Research Global Investors Increases Stock Position in Biohaven Ltd. $BHVN

Capital Research Global Investors boosted its stake in Biohaven Ltd. (NYSE:BHVN) by 31.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,332,792 shares of the company’s stock after purchasing an additional 321,262 shares during the quarter. Capital Research Global Investors owned about 1.26% of Biohaven worth $15,047,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of BHVN. AQR Capital Management LLC raised its stake in Biohaven by 49.4% in the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company’s stock valued at $2,761,000 after purchasing an additional 37,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Biohaven by 32.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company’s stock valued at $1,747,000 after purchasing an additional 17,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Biohaven by 7.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company’s stock worth $14,174,000 after acquiring an additional 41,040 shares in the last quarter. Intech Investment Management LLC raised its stake in shares of Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company’s stock worth $1,481,000 after acquiring an additional 27,433 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in shares of Biohaven by 1,097.8% during the second quarter. Quantbot Technologies LP now owns 8,840 shares of the company’s stock worth $125,000 after acquiring an additional 8,102 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. TD Cowen lifted their price target on shares of Biohaven from $15.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. HC Wainwright reissued a “neutral” rating and set a $10.00 price target on shares of Biohaven in a research note on Tuesday, May 26th. Royal Bank Of Canada decreased their price target on shares of Biohaven from $23.00 to $22.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Canaccord Genuity Group assumed coverage on shares of Biohaven in a research note on Monday, April 13th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Citigroup lifted their price target on shares of Biohaven from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.27.

Biohaven Stock Performance

NYSE:BHVN opened at $11.11 on Wednesday. The stock has a market cap of $1.67 billion, a P/E ratio of -1.96 and a beta of 1.35. The firm’s fifty day simple moving average is $9.84 and its 200 day simple moving average is $10.47. Biohaven Ltd. has a twelve month low of $7.48 and a twelve month high of $18.57. The company has a quick ratio of 7.41, a current ratio of 7.41 and a debt-to-equity ratio of 1.87.

Biohaven (NYSE:BHVN) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). As a group, research analysts predict that Biohaven Ltd. will post -3.07 EPS for the current year.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.